Net Income
Net income attributable to common stock
Boston Scientific Net income attributable to common stock increased by 99.6% to $1.34B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 99.0%, from $674.00M to $1.34B. Over 4 years (FY 2021 to FY 2025), Net income attributable to common stock shows an upward trend with a 31.0% CAGR.
Analysis
StatementIncome Statement
SectionNet Income
First reportedQ1 2018
Last reportedQ1 2026May 1, 2026
Metric ID:
t_net_income_attributable_to_common_stockHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $172.00M | $405.00M | $80.00M | $97.00M | $246.00M | $174.00M | $126.00M | $300.00M | $261.00M | $505.00M | $505.00M | $495.00M | $324.00M | $469.00M | $565.00M | $674.00M | $797.00M | $755.00M | $672.00M | $1.34B |
| QoQ Change | — | +135.5% | -80.2% | +21.3% | +153.6% | -29.3% | -27.6% | +138.1% | -13.0% | +93.5% | +0.0% | -2.0% | -34.5% | +44.8% | +20.5% | +19.3% | +18.2% | -5.3% | -11.0% | +99.6% |
| YoY Change | — | — | — | — | +43.0% | -57.0% | +57.5% | +209.3% | +6.1% | +190.2% | +300.8% | +65.0% | +24.1% | -7.1% | +11.9% | +36.2% | +146.0% | +61.0% | +18.9% | +99.0% |
Range$80.00M – $1.34B
CAGR+54.1%
Avg YoY Growth+75.3%
Median YoY Growth+50.3%
Net income attributable to common stock at Other Companies
Frequently Asked Questions
- What is Boston Scientific's net income attributable to common stock?
- Boston Scientific (BSX) reported net income attributable to common stock of $1.34B in Q1 2026.
- How has Boston Scientific's net income attributable to common stock changed year-over-year?
- Boston Scientific's net income attributable to common stock increased by 99.0% year-over-year, from $674.00M to $1.34B.
- What is the long-term trend for Boston Scientific's net income attributable to common stock?
- Over 4 years (2021 to 2025), Boston Scientific's net income attributable to common stock has grown at a 31.0% compound annual growth rate (CAGR), from $984.00M to $2.90B.